Palisade Bio Q2 2024 GAAP EPS $(3.32) Misses $(3.11) Estimate
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio (NASDAQ:PALI) reported a Q2 2024 GAAP EPS of $(3.32), missing the analyst consensus estimate of $(3.11) by 6.75%.
August 13, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Palisade Bio reported a Q2 2024 GAAP EPS of $(3.32), missing the analyst consensus estimate of $(3.11) by 6.75%. This miss could negatively impact the stock price in the short term.
The reported EPS miss indicates that the company's performance was worse than expected, which typically leads to a negative reaction from investors and a potential drop in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100